UCFA
PDSB icon

United Capital Financial Advisors’s PDS Biotechnology PDSB Stock Holding History

United Capital Financial Advisors’s Portfolio PDSB Stock Details PDSB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$7.26K Buy
+12,000
New +$9.03K ﹤0.01% 1630

Other funds holding PDSB

VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
William Blair & Company
William Blair & Company Chicago, Illinois $34.9B AUM 18.88% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
IWA
Inspirion Wealth Advisors Libertyville, Illinois $874M AUM 16.23% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

United Capital Financial Advisors's PDSB Position: Q1 2026 in Review

United Capital Financial Advisors opened a new position in PDS Biotechnology (PDSB) in Q1 2026: 12,000 shares worth $7.26K. The stake represents ﹤0.01% of the portfolio and ranks #1630 among its holdings.

41 funds tracked by Wall St. Rank hold PDSB as of Q1 2026.

  • United Capital Financial Advisors held 12,000 shares of PDS Biotechnology worth $7.26K as of Q1 2026.
  • PDS Biotechnology was a new United Capital Financial Advisors position in Q1 2026.
  • PDS Biotechnology made up ﹤0.01% of United Capital Financial Advisors's portfolio in Q1 2026, its #1630 holding.
  • 41 funds tracked by Wall St. Rank held PDS Biotechnology as of Q1 2026.

Based on United Capital Financial Advisors's 13F filing for Q1 2026, filed 15 May 2026.